TTI Share Price Performance
CA$0.75
0.15 (25.00%)
Price CA$0.75
Share PriceCA$0.75
Thiogenesis Therapeutics, Corp. Stock Price
- 0 Narratives written by author
- 0 Comments on narratives written by author
- 0 Fair Values set on narratives written by author
TTI Community Narratives
There are no narratives available yet.
There are no community narratives available.
Snowflake Analysis
Thiogenesis Therapeutics, Corp. Key Details
About TTI
- Founded
- n/a
- Employees
- n/a
- CEO
- WebsiteView website
Thiogenesis Therapeutics, Corp., a clinical-stage biopharmaceutical company, develops thiol-based therapeutic compounds to treat unmet pediatric medical needs. Its lead product candidate is TTI-0102, a prodrug that consists of cysteamine for use in the treatment of mitochondrial encephalopathy lactic acidosis and stroke-like episodes, leigh syndrome, pediatric metabolic dysfunction-associated steatohepatitis, and rett syndrome. The company is headquartered in Toronto, Canada.
